ObsEva SA today announced that IMPLANT 2 Phase 3 clinical data of its novel, oral, oxytocin receptor antagonist, nolasiban, in patients undergoing IVF were presented at the 74th annual meeting ofthe American Society of Reproductive Medicine (ASRM), taking place in Denver, Colorado, October 6-10, 2018.
October 12, 2018
· 6 min read